Document:

Exhibit
10.2

 

SHARE
PURCHASE AGREEMENT

 

THIS
SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 29, 2022 (the “Effective Date”),
by and between Qualigen Therapeutics Inc. (the “Purchaser”) and Alpha Capital Anstalt (the “Seller”).

 

W
I T N E S S E T H:

 

WHEREAS,
the Seller owns and desires to sell 2,232,861 Preferred A-1 Shares, nominal value NIS 0.01 each (the “Purchased Shares”),
of NanoSynex Ltd., an Israeli company (the “Company”);

 

WHEREAS,
the Purchaser has expressed its desire to purchase from the Seller, and the Seller has agreed to sell and transfer to the Purchaser the
Purchased Shares, for a price per Purchased Share of US$1.5672 (the “PPS”), for an aggregate purchase price of US$ 3,500,000
(the “Purchase Price”), which Purchase Price shall be paid in shares of common stock, par value $0.001 per share (the “Common
Stock”), of the Purchaser, subject to the terms set forth herein.

 

WHEREAS,
the Purchaser, concurrently with the transaction contemplated herein, is investing additional amounts in the Company in accordance with
and pursuant to the terms set forth in that certain Series B Preferred Share Purchase Agreement (the “Main SPA”) of even
date herewith (such transaction described therein, the “Series B Financing”);

 

WHEREAS,
the Seller has agreed to, concurrently with the consummation of the Series B Financing, (i) sell the Purchased Shares to Purchaser and
(ii) transfer and assign to the Purchaser all of its rights under the Series A Preferred Share Purchase Agreement dated September 20,
2018 (the “Series A SPA”), by and among the Company, the Founders, the Purchaser and the Lenders (as such terms are defined
in the Series A SPA); and

 

WHEREAS,
the Series B Financing is inter alia contingent upon the completion of the transactions contemplated herein, and the transactions contemplated
herein are inter alia contingent upon the completion of the Series B Financing;

 

NOW
THEREFORE, intending to be legally bound, the parties agree as follows:

 

ARTICLE
I. PURCHASE PRICE.

 

1.01
Purchase and Sale. Upon the terms and subject to the conditions of this Agreement (including the payment of the Purchase Price), the
Seller agrees to sell to the Purchaser and the Purchaser agrees to purchase from the Seller at the Closing (as defined below), the Purchased
Shares.

 

1.02
Tax Withholding. The Purchaser shall be entitled to deduct and withhold from any consideration payable by it to Seller pursuant to this
Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payments under the Israeli Income
Tax Ordinance (New Version) 1961, unless Seller provides the Purchaser with an applicable withholding certificate issued by the Israeli
Tax Authority (the “ITA” and “Tax Withholding Certificate”, respectively) with respect to the Seller, which certificate
exempts the Purchaser from such withholding requirement or reduces the withholding tax due in respect of such payment, in which case
the taxes shall not be withheld, or shall be deducted and withheld from any consideration payable or otherwise deliverable to Seller
pursuant to this Agreement at the reduced rate as indicated in the Tax Certificate, and the balance of the Purchase Price payable to
the Seller not so withheld shall be promptly paid to the Seller. For the avoidance of doubt, to the extent that Seller does not obtain
prior to Closing a Tax Withholding Certificate that exempts the Purchaser from withholding tax (i.e., either Purchaser needs to withhold
the full tax amount or just a reduced tax rate), then Seller shall transfer to Purchaser cash in an amount equivalent to such amounts
as Purchaser is required to deduct and withhold with respect to the Purchase Price under the Israeli Income Tax Ordinance (New Version)
1961. To the extent that amounts are so withheld by the Purchaser, the Purchaser shall (i) promptly pay such amounts to the ITA and (ii)
promptly provide the Seller with written confirmation as to the amount so withheld. Any withheld amounts shall be treated for all purposes
of this Agreement as having been paid to the Seller as part of the Purchase Price due to the Seller from the Purchaser hereunder. To
the extent that the Purchase Price is not reduced (or is not sufficiently reduced) by the Purchaser or taxes are not otherwise properly
paid by the Seller and as a result thereof the Purchaser is required to pay amounts above and beyond the Purchase Price (the “Excess
Amount”) to the ITA or any other governmental or regulatory authority due to the sale and purchase of the Purchased Shares, the
Seller shall indemnify the Purchaser for any such Excess Amount.

 

    	 

     

    

 

1.03
Closing. The transactions contemplated in this Agreement shall take place concurrently with and conditioned upon the closing of the Main
SPA via the exchange of documents and signatures (the “Closing”).

 

1.04
Closing Transactions. At the Closing, the following transactions shall occur, which transactions shall be deemed to take place simultaneously
and no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed and
all required documents delivered:

 

(a)
The Purchaser shall deliver:

 

(i)
to the Seller, the Purchase Price (for the avoidance of any doubt, without deduction or withholding of any amounts therefrom), by way
of issuance of a number of shares of Common Stock (the “Consideration Shares”), equal to the Purchase Price divided by the
Nasdaq Official Closing Price of the Purchaser’s Common Stock as listed on the Nasdaq Capital Market on the last business day prior
to the date of the Closing; provided however, that in the instance that the total number of Consideration Shares to be issued to the
Seller shall be greater than 9.9% of the total shares of Purchaser’s Common Stock issued and outstanding at the time of payment
of the Purchase Price, inclusive of the issuance of the Consideration Shares representing the Purchase Price (the “Maximum Common
Stock Issuance”), then the Purchaser shall only issue to the Seller such number of shares of Common Stock that represent the Maximum
Common Stock Issuance, and the difference between the total Purchase Price and the aggregate value of the Consideration Shares issued
by the Purchaser to Seller shall instead be issued as pre-funded common stock warrants in the form attached hereto as Exhibit A (the
“Pre-Funded Warrants”); and

 

(ii)
to the Company, the Share Transfer Deed (as defined below) signed by the Purchaser.

 

(b)
Seller shall deliver the following documents:

 

(i)
to the Purchaser, a duly authorized and executed share transfer deed, in the form attached hereto as Exhibit B, effecting the transfer
of the Purchased Shares from the Seller to the Purchaser (the “Share Transfer Deed”);

 

(ii)
to the Purchaser, the original share certificate issued to the Seller representing the Purchased Shares for cancellation by the Company
or an affidavit of lost share certificate(s) in a form acceptable to the Company executed by the Seller; and

 

(iii)
to the Purchaser, a duly authorized and executed assignment of rights agreement in the form attached hereto as Exhibit C effecting the
assignment of Seller’s rights under the Series A SPA to the Purchaser (the “Assignment of Rights”).

 

ARTICLE
II. REPRESENTATIONS, WARRANTIES AND ACKNOWLEDGEMENTS OF THE SELLER

 

The
Seller represents and warrants to the Purchaser as of the Effective Date and as of the Closing, acknowledging that the Purchaser is relying
on Seller’s representations in entering into the transactions to purchase the Purchased Shares, as follows:

 

2.01
Existence and Power. The Seller is an entity duly established and validly existing under the laws of its jurisdiction of incorporation
or formation and has all corporate or entity powers and authorizations to carry on its business as now being conducted and to execute
and deliver this Agreement and any ancillary documents and to consummate the transactions contemplated hereby.

 

2.02
Authorization. The execution, delivery and performance by the Seller of this Agreement and the consummation of the transactions contemplated
hereby have been duly authorized by all necessary corporate, entity or partnership action on its part. This Agreement constitutes a valid
and binding agreement of the Seller, enforceable against the Seller in accordance with its terms, subject to laws of general application
relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other
equitable remedies. No consent, approval, order, license, permit, action by, or authorization of or designation, declaration, or filing
with any person or governmental authority is required that has not been, or will not have been, obtained by the Purchaser prior to the
Closing in connection with the valid execution, delivery and performance of this Agreement and any ancillary documents and the transfer
of the payment of the Purchase Price to the Seller.

    	 

     

    

 

2.03
Non-contravention. The execution, delivery and performance of this Agreement does not and will not, contradict or violate, result in
a breach of, or constitute a default under: (i) any court ruling or decree, any decision of a quasi-judicial body or any administrative
order or decision in any country to which the Seller is subject or by which the Shares are bound; (ii) any agreement, instrument, obligation
or restriction to which the Seller is a party or by which the Seller or any Purchased Shares are bound; or (iii) any applicable law.

 

2.04
Transfer Restrictions. The Seller has the full and unrestricted legal right to sell and transfer the Purchased Shares to the Purchaser
as provided herein, subject to the restrictions on transfer imposed by the Company’s Corporate Documents (as defined below). The
Seller is selling the Purchased Shares for its own account and is not acting as an agent, representative, intermediary, nominee or in
a similar capacity for any other person or entity, nominee account or beneficial owner. The Purchased Shares have not been registered
under the United States Securities Act of 1933, as amended (the “Act”), or any other securities laws, and after transfer
to the Purchaser pursuant hereto, each Purchased Share will be subject to the transfer restrictions contained in the Company’s
Corporate Documents. All provisions governing any transfer or assignment restrictions specified in any of the Company’s Corporate
Documents have been (or will have been prior to or at the Closing) complied with (or waived in writing by the beneficiaries thereof)
in respect of the sale of the Purchased Shares contemplated herein, and, pursuant to the Company’s Corporate Documents (and subject
to compliance with their terms) and to applicable law, the Seller is free to sell the Purchased Shares to the Purchaser in the manner
contemplated herein. For purposes of this Agreement, the term “Corporate Documents” means the Company’s Amended and
Restated Articles of Association (the “Amended Articles”) and the Investors’ Rights Agreement between the Company and
certain of its shareholders in each case effect as of the Closing.

 

2.05
Ownership of the Purchased Shares. The Seller is the legal and beneficial owner of the Purchased Shares, free and clear of any liens,
charges, judgments, security interests, encumbrances, debt, limitations or restrictions (including, but not limited to, any restriction
on the right to vote, sell or otherwise dispose of the Purchased Shares, any mortgage, pledge, charge, title retention, right to acquire,
hypothecation, option, right of first offer, tag along or right of first refusal), rights, claims, options to purchase, proxies, voting
trusts and other voting agreements, calls and commitments of any kind, or third party rights of any kind, (collectively, “Liens”),
other than as set forth in Company’s Corporate Documents and will transfer and deliver to the Purchaser at the Closing valid title
to the Purchased Shares free and clear of any Liens, other than as set forth in Company’s Corporate Documents. Immediately following
the Closing, the Purchaser shall be the sole owner of the Purchased Shares free and clear of all Liens, other than any future restrictions
on the sale and transfer of the Purchased Shares set forth in the Company’s Corporate Documents (it being clarified that the Company’s
Corporate Documents do not restrict the sale and transfer of the Purchased Shares to the Purchaser as contemplated under this Agreement,
except such aforementioned restrictions which have been complied with or waived in writing by the beneficiaries thereof).

 

2.06
Certain Conduct. Except as set forth in this Agreement, the Seller has not (i) sold, assigned, transferred, delivered, or otherwise disposed
of the Purchased Shares, (ii) converted, exchanged or redeemed any of the Purchased Shares, (iii) taken any action which would cause
the amendment, cancellation or termination of any governing document pertaining to the Company, (iv) created or permitted to exist any
Lien on the Purchased Shares, (v) taken any action or failed to take any action the effect of which would be to cause the Purchaser to
incur a penalty or other specified consequences under the applicable governing documents of the Company or (vi) agreed to do any of the
foregoing.

 

2.07
No Bankruptcy; No Dissolution. The Seller has never filed any petition under applicable bankruptcy laws, no such petition has ever been
filed involuntarily against the Seller, no custodian or receiver has ever been appointed with respect to the Seller’s assets, and
the Seller is not insolvent (before or after giving effect to the sale of the Purchased Shares).

 

2.08
Litigation. There is no action, suit, investigation or proceeding pending against or threatened in writing against the Seller before
any court, arbitrator or any governmental authority which, individually or in the aggregate, if determined or resolved adversely in accordance
with the plaintiff’s demands, could challenge or seek to prevent, enjoin, alter or materially delay the transactions contemplated
by this Agreement.

 

2.09
No Continuing Rights. The Seller hereby acknowledges that following the Closing, Seller shall have no rights with respect to the Purchased
Shares, as a shareholder of the Company or otherwise, including, without limitation with respect to any ownership interest in the Purchased
Shares, rights to distributions or the proceeds of any future sale, acquisition, merger, liquidation, dissolution or other similar event
regarding the Company (any of the foregoing, a “Liquidation Transaction”). Seller further acknowledges that any such Liquidation
Transaction may result in the payment by the Company or a third party of assets, funds or other proceeds to the Company’s shareholders
in a manner such that the value attributed to the Purchased Shares in such Liquidation Transaction may be greater than the Purchase Price.
Further, the Seller acknowledges that the market value of the Purchased Shares could, in the future and depending on the success of the
Company’s business, become worth substantially more than the Purchase Price.

 

    	 

     

    

 

2.10
Sophistication; Non-Reliance on Purchaser; Purchase Price. The Seller is a sophisticated, experienced investor, capable of evaluating
the value of the Purchased Shares and the Consideration Shares (and the Pre-Funded Warrants, if any), has made its own due diligence
analysis in its decision to sell the Purchased Shares to the Purchaser in exchange for the Consideration Shares (and Pre-Funded Warrants,
if applicable), pursuant to this Agreement, can bear the economic risk of an investment in the Consideration Shares (and Pre-Funded Warrants,
if applicable), and has not relied in connection with the sale of the Purchased Shares to Purchaser in exchange for the Consideration
Shares (and Pre-Funded Warrants, if applicable) upon any representations, warranties or agreements of the Purchaser other than those
set forth in this Agreement. The Purchaser has no obligation to provide information to the Seller relating to the value of the Purchased
Shares, the Consideration Shares, the Pre-Funded Warrants, if any, or otherwise. The Seller acknowledges that the Purchase Price represents
a negotiated price and may not reflect the fair market value of the Purchased Shares. The Seller has had the opportunity to ask the Company
questions and receive information and has received all the information it considers necessary or appropriate for deciding whether to
sell the Purchased Shares to the Purchaser in exchange for the Consideration Shares (and Pre-Funded Warrants, if applicable) pursuant
to this Agreement. The Seller has had the opportunity to ask the Purchaser questions and receive information and has received all the
information it considers necessary or appropriate for deciding whether to sell the Purchased Shares to the Purchaser in exchange for
the Consideration Shares (and Pre-Funded Warrants, if applicable). The Seller acknowledges that (i) neither the Purchaser, the Company
nor their respective Related Parties (as defined below) has made any representation or warranty to the Seller, express or implied, except
for any representations or warranties of the Purchaser that are expressly set forth in this Agreement, regarding any aspect of the sale
and purchase of the Purchased Shares or the Consideration Shares (and any Pre-Funded Warrants, if applicable), the operation or financial
condition of the Company or the Purchaser or the value of the Purchased Shares or the Consideration Shares (or the Pre-Funded Warrants,
if applicable), (ii) the Seller is not relying upon the Purchaser, the Company or their respective Related Parties in making its decision
to sell the Purchased Shares to the Purchaser in exchange for the Consideration Shares (and Pre-Funded Warrants, if applicable) pursuant
to this Agreement and (iii) the Purchaser is relying upon the truth of the representations and warranties in this Article III in connection
with the purchase of the Purchased Shares in exchange for the Consideration Shares (and Pre-Funded Warrants, if applicable) hereunder.
The Seller further acknowledges that none of the Purchaser, the Company nor their respective Related Parties is acting as a fiduciary
or financial or investment advisor to the Seller, and none of such parties has given the Seller any investment advice, opinion or other
information on whether the sale of the Purchased Shares in exchange for the Consideration Shares (and Pre-Funded Warrants, if applicable)is
prudent. For purposes of this Agreement, “Related Parties” shall mean current and former directors, managers, officers, partners,
employees, attorneys, agents, successors, assigns, shareholders, members, partners or other equity owners, representatives, predecessors,
parents, affiliates, associates and subsidiaries, and their respective successors and assigns.

 

2.11
Taxes. The Seller acknowledges that none of the Purchaser, the Company or the Related Parties of Purchaser or the Company has made any
representation to, or provided any legal, tax or investment advice to, the Seller with respect to the tax treatment of the transactions
contemplated by this Agreement. The Seller acknowledges that the execution of this Agreement and the sale of the Purchased Shares may
have immediate tax consequences and that any tax liability triggered as a result of the sale of the Purchased Shares by the Seller shall
be borne exclusively by the Seller. Neither Seller nor any of its limited and/or general partners is an Israeli residence for tax purposes.

 

2.12
Purchased Shares Authorized. To Seller’s knowledge, the Purchased Shares have been duly authorized and are validly issued, fully
paid and non-assessable.

 

2.13
Brokers and Finders. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in
connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

 

2.14
No Broker-Dealer. The Seller has not effected this sale of Purchased Shares through a broker-dealer in any public offering.

 

2.15
No General Solicitation. At no time has the Purchaser presented the Seller or any Related Parties of the Seller with, or solicited the
Seller or any Related Parties of the Seller through, any publicly issued or circulated newspaper, mail, radio, television, internet or
other form of general advertisement or solicitation in connection with the sale of the Purchased Shares or the purchase of the Consideration
Shares (and any Pre-Funded Warrants, if applicable).

 

    	 

     

    

 

2.16
Accredited Investor. Seller is an “accredited investor” within the meaning of Rule 501 of Regulation D of the Act, as presently
in effect.

 

2.17
Sale Exempt. The Seller has not offered any of the share capital of the Company held by it for sale to, or solicited any offers to buy
any of the foregoing, or otherwise approached or negotiated with any other person in respect thereof, in such a manner as to require
registration of the Purchased Shares under the Act or the comparable law of any other jurisdiction.

 

2.18
Purchase Exempt. The Seller is acquiring the Consideration Shares (and any Pre-Funded Warrants, if applicable) from Purchaser solely
for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof.
Seller acknowledges that the Consideration Shares (and any Pre-Funded Warrants, if applicable) to be issued to it have not been registered
under the Act or any state securities laws, and that the Consideration Shares may not be transferred or sold except pursuant to the registration
provisions of the Act or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable.

 

ARTICLE
III. REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

 

The
Purchaser represents and warrants to the Seller as of the Effective Date and as of the Closing, as follows:

 

3.01
Existence and Power. The Purchaser is an entity duly established and validly existing under the laws of its jurisdiction of incorporation
or formation and has all corporate or entity powers and authorizations to carry on its business as now being conducted and to execute
and deliver this Agreement and any ancillary documents and to consummate the transactions contemplated hereby.

 

3.02
Authorization. The execution, delivery and performance by the Purchaser of this Agreement and the consummation of the transactions contemplated
hereby are within its powers and have been duly authorized by all necessary corporate, entity or partnership action on its part. This
Agreement constitutes a valid and binding agreement of the Seller, enforceable against the Seller in accordance with its terms, subject
to laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance,
injunctive relief or other equitable remedies. No consent, approval, order, license, permit, action by, or authorization of or designation,
declaration, or filing with any person or governmental authority is required that has not been, or will not have been, obtained by the
Purchaser prior to the Closing in connection with the valid execution, delivery and performance of this Agreement and any ancillary documents
and the transfer of the payment of the Purchase Price to the Seller.

 

3.03
Litigation. There is no action, suit, investigation or proceeding pending against or threatened in writing against the Purchaser before
any court, arbitrator or any governmental authority which, individually or in the aggregate, if determined or resolved adversely in accordance
with the plaintiff’s demands, could reasonably be expected to challenge or seek to prevent, enjoin, alter or materially delay the
transactions contemplated by this Agreement.

 

3.04
Sophistication; Non-Reliance on Seller. The Purchaser is a sophisticated, experienced investor, capable of evaluating the value of the
Purchased Shares, has made its own due diligence analysis in its decision to purchase the Purchased Shares to the Purchaser in exchange
for the Consideration Shares (and Pre-Funded Warrants, if applicable) pursuant to this Agreement, can bear the economic risk of an investment
in the Purchased Shares, and has not relied in connection with the purchase of the Purchased Shares in exchange for the Consideration
Shares (and any Pre-Funded Warrants, if applicable) upon any representations, warranties or agreements of the Seller or the Company other
than those set forth in this Agreement. The Seller has no obligation to provide information to the Purchaser relating to the value of
the Purchased Shares, or otherwise. The Purchaser acknowledges that the Purchase Price represents a negotiated price and may not reflect
the fair market value of the Purchased Shares. Purchaser has had the opportunity to ask the Company questions and receive information
and has received all the information it considers necessary or appropriate for deciding whether to purchase the Purchased Shares pursuant
to this Agreement in exchange for the Consideration Shares (and Pre-Funded Warrants, if applicable). The Purchaser acknowledges that
(i) neither the Seller, the Company nor their respective Related Parties has made any representation or warranty to the Purchaser, express
or implied, except for any representations or warranties of the Seller that are expressly set forth in this Agreement, regarding any
aspect of the sale and purchase of the Purchased Shares or the Consideration Shares (and any Pre-Funded Warrants, if applicable), the
operation or financial condition of the Company or the value of the Purchased Shares, (ii) the Purchaser is not relying upon the Seller,
the Company or their respective Related Parties in making its decision to purchase the Purchased Shares in exchange for the Consideration
Shares (and any Pre-Funded Warrants, if applicable) pursuant to this Agreement and (iii) the Seller is relying upon the truth of the
representations and warranties in this Article III in connection with the sale of the Purchased Shares in exchange for the Consideration
Shares (and any Pre-Funded Warrants, if applicable) hereunder. The Purchaser further acknowledges that none of the Seller, the Company
nor their respective Related Parties is acting as a fiduciary or financial or investment advisor to the Purchaser, and none of such parties
has given the Purchaser any investment advice, opinion or other information on whether the purchase of the Purchased Shares in exchange
for the Consideration Shares (and any Pre-Funded Warrants, if applicable) is prudent.

 

    	 

     

    

 

3.05
Purchase Exempt. The Purchaser is acquiring the Purchaser Shares from Seller solely for its own account for investment purposes and not
with a view to, or for offer or sale in connection with, any distribution thereof. Purchaser acknowledges that the Purchaser Shares to
be issued to it have not been registered under the Act or any state securities laws, and that the Purchase Shares may not be transferred
or sold except pursuant to the registration provisions of the Act or pursuant to an applicable exemption therefrom and subject to state
securities laws and regulations, as applicable.

 

3.06
Accredited Investor. Purchaser is an “accredited investor” within the meaning of Rule 501 of Regulation D of the Act, as
presently in effect.

 

3.07
No Public Market. The Purchaser understands that no public market now exists for the Purchased Shares and that the Company has made no
assurances that a public market will ever exist for the Purchased Shares.

 

ARTICLE
IV. COVENANTS OF THE PURCHASER AND THE SELLER

 

4.01
Best Efforts. Subject to the terms and conditions of this Agreement, the Purchaser and the Seller will use their best efforts to take,
or cause to be taken, all actions and to do, or cause to be done, all things necessary or desirable to consummate the transactions contemplated
by this Agreement.

 

4.02
Cooperation. The Seller and the Purchaser shall cooperate with one another (i) in determining whether any action by or in respect of,
or filing with, any governmental authority is required, or any waivers, actions, consents or approvals are required to be obtained from
the Company or third parties, in connection with the consummation of the transactions contemplated by this Agreement; and (ii) in taking
such actions, making any such filings or furnishing any information required in connection therewith and timely seeking to obtain any
such actions, consents, approvals or waivers.

 

4.03
Resale Registration Statement. As soon as reasonably practicable following the issuance of the Consideration Shares, but in any event
within thirty (30) days following the issuance of the Consideration Shares, the Purchaser shall file with the Securities and Exchange
Commission (the “SEC”) a registration statement on Form S-1 or Form S-3 pursuant to Rule 415 (the “Resale Registration
Statement”) under the Act, pursuant to which all of the Consideration Shares and shares issuable upon exercise of the pre-Funded
Warrants shall be registered to enable the public resale on a delayed or continuous basis of the Consideration Shares by the Seller.
The Purchaser shall use its commercially reasonable efforts to have the Resale Registration Statement declared effective under the Securities
Act as soon as reasonably practicable.

 

4.04
Registration Statement Questionnaire. The Seller shall provide the Purchaser with a completed and executed stockholder questionnaire
in the form attached hereto as Exhibit D within ten (10) days of the date of this Agreement (the “Questionnaire”). Notwithstanding
anything to the contrary contained in this Agreement, if the Seller has not returned a completed and executed Questionnaire within thirty
(30) days following the issuance of the Consideration Shares, the Purchaser shall not be obligated to file the Resale Registration Statement
in accordance with Section 5.03 until the date that is ten (10) days after the date the Seller delivers the completed and executed Questionnaire
to the Purchaser.

 

4.05
Waiver and Release. Seller hereby releases, remises and forever discharges the Purchaser, the Company and each of their respective Related
Parties (the “Purchaser Released Parties”), from any and all actions, causes of action, claims, demands, rights, suits, accountings,
debts, dues, accounts, bonds, covenants, contracts, agreements, duties and obligations of whatsoever kind or nature, whether at law or
in equity, or otherwise known or unknown, by reason of any matter or thing whatsoever (collectively, “Claims”) which the
Seller has, had or may have against any Purchaser Released Parties in its capacity as a shareholder of the Company with respect to the
Purchased Shares, in connection with the sale of the Purchased Shares on or prior to the Closing, or the Seller’s ownership and
sale of the Purchased Shares, other than any Claims against the Purchaser or the Company that may result from the transactions contemplated
by this Agreement and the promissory notes between Seller and the Company dated as of March 16, 2020, March 24, 2021, September 2, 2021
and October 27, 2021 in the aggregate principal amount of $900,000, which shall remain in full force and effect. The Seller represents
and warrants that it has not initiated any Claims against any Purchaser Released Parties relating to the Purchased Shares and that it
has not assigned any Claims against any Purchaser Released Parties relating to the Purchased Shares to any other person or entity.

 

    	 

     

    

 

4.06
No Sale Below Purchase Price. The Purchaser shall not sell any shares of its Common Stock (or any security convertible or exchangeable
into its Common Stock) at a price below the Purchase Price per share until 30 days after the effective date of the resale registration
statement.

 

ARTICLE
V. CONDITIONS TO CLOSING

 

5.01
Conditions to Obligation of the Purchaser. The obligation of the Purchaser to consummate the Closing with respect to the Seller is subject
to the satisfaction, on or prior to the Closing of each the following conditions, any or all of which may be waived by the Purchaser
in its sole discretion:

 

(a)
The Seller shall have performed in all respects all of their obligations hereunder required to be performed by them on or prior to the
Closing.

 

(b)
The representations and warranties of the Seller contained in this Agreement shall be true and correct in all respects as of the Effective
Date and as of the Closing, as if made at and as of such date.

 

(c)
All conditions to the closing of the Series B Financing shall have been satisfied in accordance with the Main SPA and closing of the
Series B Financing shall have occurred.

 

(d)
All of the documents to be delivered by the Seller to the Purchaser pursuant to Article ‎1.04(b) shall have been delivered to the
Purchaser on or before the Closing.

 

(e)
The Seller shall have received all of the consents, authorizations and approvals that are required under applicable law or the Company’s
Corporate Documents for the consummation of the transactions contemplated by this Agreement.

 

(f)
No action, suit, litigation, arbitration, proceeding or investigation shall been instituted, be pending or be threatened against the
Seller with regard to the transactions contemplated by this Agreement.

 

(g)
The Seller shall have provided the Purchaser with a Tax Withholding Certificate with respect to the Seller exempting the Purchaser from
withholding tax in respect of the Purchase Price obtained from the ITA, or, to the extent that Seller does not obtain a Tax Withholding
Certificate that exempts the Purchaser from withholding tax (i.e. either Purchaser needs to withhold the full tax amount or just a reduced
tax rate), then Seller shall transfer to Purchaser cash in an amount equivalent to such amounts as Purchaser is required to deduct and
withhold with respect to the Purchase Price under the Israeli Income Tax Ordinance (New Version) 1961.

 

5.02
Conditions to Obligation of the Seller. The obligation of the Seller to consummate the Closing is subject to the satisfaction, on or
prior to the Closing of each of the following conditions, any or all of which may be waived by the Seller in its sole discretion.

 

(a)
The Purchaser shall have performed in all respects all of Purchaser’s agreements, obligations and conditions hereunder required
to be performed by the Purchaser at or prior to the Closing, including the payment by the Purchaser of the Purchase Price and the transfer
thereof to the Seller.

 

(b)
The representations and warranties of the Purchaser contained in this Agreement shall be true and correct in all respects as of the Effective
Date and as of the Closing, as if made at and as of such date.

 

ARTICLE
VI. MISCELLANEOUS

 

6.01
Survival of Warranties. The warranties, representations and covenants of the Seller contained in or made pursuant to this Agreement shall
survive the execution and delivery of this Agreement and the Closing, and shall in no way be affected by any investigation of the subject
matter thereof made by or on behalf of the Purchaser.

 

6.02
Notices. All notices and other communications required or permitted hereunder to be given to a party to this Agreement shall be in writing
and shall be sent by facsimile, email or mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand or by
messenger, addressed to such party’s address as set forth in each party’s signature page below or at such other address as
the party shall have furnished to each other party in writing in accordance with this provision.

 

    	 

     

    

 

6.03
Amendments, Waivers and Remedies. Any provision of this Agreement may be amended, waived, or discharged (either prospectively or retroactively,
and either generally or in a particular instance), by a written instrument signed by the Seller and the Purchaser. No failure, delay
or omission by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single
or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. Any
waiver, permit, consent, or approval of any kind or character on the part of any party of any breach or default under this Agreement,
or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only
to the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law, or otherwise afforded to
any of the parties, shall be cumulative and not alternative.

 

6.04
Public Announcements. Except as required by law (including SEC rules), no party shall issue any press release, publish any circular or
issue or release any other public statement or disclose to any person any information, in each case relating to or connected with or
arising out of this Agreement or the matters contained herein, without the prior written approval of the other parties to its contents
and the manner of its presentation and publication. Nothing in the foregoing shall prevent the Purchaser from disclosing the terms of
this Agreement to (i) its lawyers, accountants and other professional advisors and (ii) its investors and limited partners (provided
that they shall be bound by a confidentiality obligation with respect to such information).

 

6.05
Successors and Assigns. Except as otherwise expressly stated to the contrary herein, the provisions hereof shall inure to the benefit
of, and be binding upon, the successors, assigns under law, heirs, executors, and administrators of the parties hereto and their respective
successors and assigns; provided that no party may assign, delegate or otherwise transfer any of its rights or obligations under this
Agreement without the consent of each other party hereto.

 

6.06
Governing Law; Jurisdiction. This Agreement shall be governed by and construed according to the laws of the State of New York, USA, without
regard to the conflict of laws provision thereof. Any claim arising under or in connection with this Agreement shall be resolved exclusively
in the appropriate courts of the State of New York, USA. Each of the parties hereby irrevocably consents to the exclusive jurisdiction
of such courts and waives and agrees not to assert any objection to the jurisdiction or convenience thereof.

 

6.07
Third Party Beneficiaries. No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations, or liabilities
hereunder upon any person other than the parties hereto, their respective Related Parties, and their respective successors and assigns.

 

6.08
Further Assurances. Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably be
necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected thereby.

 

6.09
Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement between the parties with respect
to the subject matter of this Agreement and supersedes all prior agreements and understandings, both oral and written, between the parties
with respect to the subject matter of this Agreement.

 

6.10
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and enforceable
against the parties actually executing such counterpart, and all of which together shall constitute one and the same instrument, and
delivery may be by facsimile, e-mail or other means of electronic transmission.

 

6.11
Heading, Preamble, and Annexes. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. The preamble and exhibits to this Agreement are an integral and inseparable part of this
Agreement.

 

6.12
Specific Performance. Each of the parties acknowledges and agrees that irreparable injury to the other parties hereto may occur if any
provision of this Agreement was not performed in accordance with its specific terms or was otherwise breached and that such injury would
not be adequately compensable in damages because of the difficulty of ascertaining the amount of damages that will be suffered if this
Agreement was breached. It is accordingly agreed that each of the parties shall be entitled, in addition to any other remedy to which
they are entitled at law or in equity, to specific enforcement of, and injunctive relief, without proof of actual damages, to prevent
any violation of the terms hereof, and the other parties hereto will not take action, directly or indirectly, in opposition to the party
seeking such relief on the grounds that any other remedy or relief is available at law or in equity. Any requirements for the securing
or posting of any bond with such remedy are hereby waived.

 

    	 

     

    

 

6.13
Severability. If any provision of this Agreement, or the application of any such provision, becomes or is declared by a court of competent
jurisdiction to be illegal, void, or unenforceable, then the remainder of this Agreement will continue in full force and effect and the
application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties
as expressed in this Agreement. The parties further agree to replace any such illegal, void, or unenforceable provision with a legal,
valid, and enforceable substitute provision that will achieve, to the greatest extent possible, the economic, business, and other purposes
of the illegal, void, or unenforceable provision.

 

6.14
Interpretation. The parties acknowledge and agree that this Agreement has been negotiated at arm’s-length and among parties equally
sophisticated and knowledgeable in the matters dealt with in this Agreement. Accordingly, any rule of law or legal decision that would
require interpretation of any ambiguities in this Agreement against the party that has drafted it is not applicable and is waived. The
provisions of this Agreement shall be interpreted in a reasonable manner to effect the intent of the parties as set forth in this Agreement.

 

6.15
Costs of Enforcement. If any party or parties seeks to enforce its rights under this Agreement by legal proceeding against any other
party, the non-prevailing party or parties named in such legal proceeding shall pay all costs and expenses incurred by the prevailing
party, including without limitation, all reasonable attorneys’ fees.

 

6.16
Voluntary Execution of the Agreement; Independent Counsel. This Agreement is executed voluntarily, without any duress or undue influence
on the part of any party or on behalf of any party. Each party acknowledge that such party has (a) read this Agreement, (b) understands
the terms and consequences of this Agreement, and (c) is fully aware of the legal and binding effect of this Agreement. Seller further
acknowledges that no legal counsel of the Purchaser has represented or acted as legal counsel to the Seller in the preparation, negotiation,
and execution of this Agreement, and that the Seller has been represented by legal counsel of the Seller’s own choice or that the
Seller has voluntarily declined to seek such counsel.

 

[Remainder
of Page Intentionally Left Blank]

[Signature
Page Follows]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have signed this Agreement as of the Effective Date.

 

	SELLER:	 
	 	 	 
	Alpha Capital Anstalt	 
	 	 	 
	By:	/s/ Nicola Feuerstein	 
	Name:	Nicola Feuerstein	 
	Title:	Director	 
	Address:	Altenbach 8 / 9490 Vaduz, Liechtenstein	 
	Email:		 

 

[Secondary
SPA (NanoSynex)– Alpha – Qualigen - Signature Page]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have signed this Agreement as of the Effective Date.

 

	PURCHASER:	 
	 	 	 
	Qualigen Therapeutics Inc.	 
	 	 	 
	By:	/s/ Michael Poirier	 
	Name:	Michael Poirier	 
	Title:	Chairman & CEO	 
	Address:	2042 Corte Del Nogal, Carlsbad, CA 92084, USA	 
	Email:		 

 

[Secondary
SPA (NanoSynex)– Alpha – Qualigen - Signature Page] 

 

    	 

     

    

 

EXHIBIT
A

 

FORM
OF PRE-FUNDED WARRANT

 

    	 

     

    

 

EXHIBIT
B

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

PRE-FUNDED
COMMON STOCK PURCHASE WARRANT

 

 

	Warrant
    Shares: [_______]	Initial
    Exercise Date: [_______], 20[__]

 

THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received,Alpha Capital Anstalt or its
assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised
in full (the “Termination Date”), but not thereafter, to subscribe for and purchase from Qualigen Therapeutics, Inc., a Delaware
corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of
the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price,
as defined in Section 2(b).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Share Purchase
Agreement (the “Purchase Agreement”), dated April 29, 2022, by and among the Company, the Holder and NanoSynex Ltd.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within
the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in
Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares
specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
The Company shall have no obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on
any Notice of Exercise nor the authority of the person so executing such Notice of Exercise. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such
notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.

 

b)
Exercise Price. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The
Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining
unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the “Exercise
Price”).

 

c)
Cashless Exercise. This Warrant may also be exercised, in whole or in part, by means of a “cashless exercise” in which the
Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in
Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common
Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours”
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after
the close of “regular trading hours” on such Trading Day;

 

(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and

 

(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).

 

    	 

     

    

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is
then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).

 

d)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered
in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number
of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any
reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period”
means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at
any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)
by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date
for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by such Warrant Share Delivery Date.

 

    	 

     

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering notice to the
Company at any time prior to the delivery of such Warrant Shares (in which case any liquidated damages payable under Section 2(d)(i)
shall no longer be payable).

 

iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to
any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price
at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the
portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to
pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of
the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to
pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant
as required pursuant to the terms hereof.

 

v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.

 

vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer
Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

    	 

     

    

 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right
to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re classification.

 

b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Warrant is outstanding
the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property
pro rata to all of the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).

 

    	 

     

    

 

c)
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to all holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance
of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the
Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in
abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation); provided that the Holder’s right to receive such Distribution shall terminate on, and shall not be held
in abeyance for any period subsequent to the Termination Date.

 

d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person and the Company is not the surviving entity,
(ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other
disposition of all or substantially all of the assets of the Company and its Subsidiaries taken as a whole in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization (other than a stock split) of the
Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or
share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization (other than
a stock split), spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity of the Company
(each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to
receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number
of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to
any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise
Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the
Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.

 

    	 

     

    

 

e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case
may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment; provided, however, that the
Company may satisfy the notice requirement in this Section 3(f) by filing such information with the Commission on its EDGAR system pursuant
to a Current Report on Form 8-K or Quarterly Report on Form 10-Q or Annual Report on Form 10-K.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form (other than
a stock split)) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights (excluding any grant or issuance of rights to all of the Company’s stockholders
pursuant to a stockholder rights plan), (D) the approval of any stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale
or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up
of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address
as it shall appear upon the Warrant Register of the Company, at least five (5) calendar days prior to the applicable record or effective
date hereinafter specified (unless such information is filed with the Commission on its EDGAR system in which case a notice shall not
be required), a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

Section
4. Transfer of Warrant.

 

a)
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in
whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

    	 

     

    

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of
this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.

 

d)
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Purchase Agreement.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the
Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

    	 

     

    

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for
the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors
of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the
defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of
Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part
of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	QUALIGEN
    THERAPEUTICS, INC.	 
	 	 	 
	 	 	 
	By:	                   	 
	Name:	 	 
	Title:	 	 

 

NOTICE
OF EXERCISE

 

	TO:	QUALIGEN
    THERAPEUTICS, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
in lawful money of the United States; or

 

[   ]
[if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 	 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

	 	 	 
	 	 	 
	 	 	 

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

Name
of Authorized Signatory: ___________________________________________________________________

Title
of Authorized Signatory: ____________________________________________________________________

Date:
________________________________________________________________________________________

 

    	 

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	 
	                (Please
    Print)	 
	 	 
	Address:	 
	 	 
	Phone
    Number:	 
	Email
    Address: (Please Print)	 
	______________________________________	 
	______________________________________	 
	Dated:
    _______________ __, ______	 
	Holder’s
    Signature:	 
	Holder’s
    Address:	 

 

FORM
OF SHARE TRANSFER DEED

 

I,
a duly authorized representative of Alpha Capital Anstalt (the “Transferor”), do hereby transfer to Qualigen Therapeutics
Inc. (the “Transferee”), 2,232,861 Preferred A-1 Shares of NanoSynex Ltd. (the “Company”), each one of NIS 0.01
nominal value, to be held by the Transferee in accordance with all the provisions of the Articles of Association of the Company and subject
to any applicable investors’ rights agreement; and I, a duly authorized representative of the Transferee, hereby accept the above-mentioned
shares to be held in accordance with all the provisions of the Articles of Association of the Company and any applicable investors’
rights agreement.

 

This
Share Transfer Deed may be executed in several counterparts, each of which shall constitute an original and all of which, when taken
together, shall constitute one deed. The exchange of a fully executed deed (in counterparts or otherwise) by electronic transmission
in PDF format or the like or by facsimile shall be sufficient to bind the parties to the terms and conditions of this deed as an original.

 

In
witness whereof, we affix our signatures hereto this __ day of ________, 2022.

 

Transferor:

 

Alpha
Capital Anstalt Transferee:

Qualigen
Therapeutics Inc.

 

	By:	 	 	By:	 
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 

 

    	 

     

    

 

EXHIBIT
C

 

ASSIGNMENT
OF RIGHTS AGREEMENT

 

    	 

     

    

 

EXHIBIT
D

 

STOCKHOLDER
QUESTIONNAIREExhibit
10.1

 

WARRANT
EXERCISE AGREEMENT

 

This
WARRANT EXERCISE AGREEMENT (the “Agreement”), dated as of May 12, 2022, is made by and between Vinco Ventures,
Inc., a Nevada corporation, with headquarters located at 6 North Main Street, Fairport, NY 14450 (the “Company”),
and the investor listed on the signature page attached hereto (the “Holder”). Capitalized terms used herein and not
otherwise defined herein shall have the respective meanings set forth in the Series A September 2021 Warrants (as defined below).

 

A.
Pursuant to that certain Warrant Exercise Agreement dated as of September 1, 2021 by and between the Company and the investor named therein
(as amended, the “September 2021 WEA”), the Company sold Series A Warrants, each representing the right to acquire
shares of Common Stock at an initial exercise price of $9.00 (the “Existing Series A September 2021 Exercise Price”),
subject to adjustments as provided therein and herein (collectively, as amended, including pursuant to the terms hereof, the “Series
A September 2021 Warrants”),

 

B.
Pursuant to the terms and conditions set forth herein, the Company and the Holder desire: (i) to adjust the Existing Series A
September 2021 Exercise Price to the Adjusted Series A September 2021 Exercise Price (as defined herein), subject to further adjustments
as provided therein and herein, pursuant to Section 2(e) of the Series A September 2021 Warrants and (ii) for the Holder to exercise
on the Closing Date such number of Series A September 2021 Warrants set forth on the Holder’s signature page attached hereto (the “Exercised
Warrants”) representing the right to acquire shares (the “Exercised Warrant Shares”) of Common Stock.

 

NOW
THEREFORE, in consideration of the foregoing mutual premises and the covenants and agreements hereinafter set forth, and for other
good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the parties hereto, intending to be
legally bound, hereby agree as follows:

 

	 	1.	AMENDMENT
    AND CASHLESS EXERCISE OF SERIES A SEPTEMBER 2021 WARRANTS. 

 

(a)
Subject to the satisfaction (or waiver) of the conditions set forth in Sections 4 and 5 below, the Company and the Holder hereby agree
that:

 

(i)
pursuant to Section 2(e) of the Series A September 2021 Warrants, from and after the date hereof through the Expiration Date (as defined
in Series A September 2021 Warrants), but subject to further adjustments as provided herein or in the Series A September 2021 Warrants,
the Existing Series A September 2021 Exercise Price shall be reduced to such Exercise Price (as defined in the Series A September 2021
Warrants) necessary in the Cashless Exercise formula set forth in Section 1(d) of the Series A September 2021 Warrants that would require
the Company at the applicable Share Delivery Date (as defined in the Series A September 2021 Warrants) to deliver 50% of a share for
each Series A September 2021 Warrant exercised pursuant to a Cashless Exercise (as defined in the Series A September 2021 Warrants) (the
“Adjusted September 2021 Exercise Price”), and immediately after giving effect to such voluntary adjustment of the
Existing Series A September 2021 Exercise Price, the Holder shall on the Closing Date exercise its Exercised Warrants into the Exercised
Warrant Shares pursuant to a Cashless Exercise (as defined therein) in accordance with Section 2(d) of the Series A September 2021 Warrants;

 

    	1

     

    

 

(ii)
the Company shall issue and deliver to the Holder the Exercised Warrant Shares as set forth in Section 1 of the Series A September 2021
Warrants.

 

(b) On or prior to the second (2nd) Business Day following the Shareholder
Approval Date (as defined below), the Company shall deliver to the Holder an additional number of Exercised Warrant Shares as additional
consideration for the exercise of the Holder’s Exercised Warrants issued on the Closing Date pursuant to Section 1(a) equal to 7.0%
of such Holder’s Exercised Warrants. As used herein, the “Shareholder Approval Date” means the later of the dates that
the Company obtains the approval of its shareholders (i) for the issuance of all the shares of Common Stock issuable pursuant to that
certain Exchange Agreement dated as of May 12, 2022 by and among the Company and the holder listed on the signature page attached thereto,
without giving effect to any limitation on exercise set forth in the Outstanding Warrants (as defined therein) or therein and without
giving effect to the 19.99% Cap (as defined therein) and (ii) of the Stockholder Resolutions (as defined in each of that certain Warrant
Exercise Agreement dated as of November 11, 2021 by and between the Company and the holder listed on the signature page attached thereto,
as amended, and that certain Warrant Exercise Agreement dated as of December 20, 2021 by and between the Company and the holder listed
on the signature page attached thereto), as amended, and effects any related amendment to its Articles of Incorporation to give effect
to such Stockholder Resolutions.

 

	 	2.	EXCHANGE;
    CLOSING.

 

(a)
Procedure. At or before the Closing, the Company shall credit to the balance account of the Holder with The Depository Trust Company
through its Deposit / Withdrawal at Custodian system (with such DWAC Instructions set forth in column (3) on Schedule I attached hereto),
the Exercised Warrant Shares.

 

(b)
Closing. The date and time of the closing (the “Closing”) of the transactions specified in Sections 1 and 2(a)
above (the “Closing Date”) shall be 9:00 a.m., New York City time, on May 19, 2022, subject to the notification
of satisfaction (or waiver) of the conditions to Closing set forth in Sections 4 and 5 hereof. The Closing shall occur at the offices
of Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022 and may be undertaken remotely by electronic exchange of
documentation.

 

    	2

     

    

 

(c)
Buy-In. If the Company shall fail for any reason or for no reason to issue to the Holder on the Closing Date the Exercised Warrant
Shares by electronic delivery at the applicable balance account at DTC, and if on or after the Closing Date the Holder effects a Buy-In,
then the Company shall, within two (2) Trading Days after the Holder’s request and in the Holder’s discretion, either (i)
pay the Buy-In Price in cash, at which point the Company’s obligation to deliver such Exercised Warrant Shares (but not the Company’s
obligation to deliver Exercised Warrants pursuant to Section 1) shall terminate, or (ii) promptly honor its obligation to electronically
deliver to the Holder such unlegended Exercised Warrant Shares as provided above and pay cash to the Holder in an amount equal to the
excess (if any) of the Buy-In Price (as defined in the Series A September 2021 Warrants) over the product of (A) such number of shares
of Common Stock, times (B) any trading price of the Common Stock selected by the Holder in writing as in effect at any time during the
period beginning on the date hereof and ending on the date the Company satisfies its obligations in full pursuant to this Section 2(c).

 

	 	3.	REPRESENTATIONS,
    AGREEMENTS, WARRANTIES AND COVENANTS.

 

(a)
Holder Representations, Warranties and Covenants. The Holder hereby represents and warrants to the Company that:

 

(i)
Authorization; Enforcement; Validity. The Holder has the power and authority to execute and deliver this Agreement and perform
its obligations hereunder; and this Agreement and the transactions contemplated hereby have been duly authorized by the Holder. This
Agreement has been duly and validly authorized, executed and delivered on behalf of the Holder and shall constitute the legal, valid
and binding obligations of the Holder enforceable against the Holder in accordance with its terms, except as such enforceability may
be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(ii)
No Conflicts. The execution, delivery and performance by the Holder of this Agreement and the consummation by the Holder of the
transactions contemplated hereby will not (i) result in a violation of the organizational documents of the Holder or (ii) conflict with,
or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Holder is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws)
applicable to the Holder, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which
would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Holder to
perform its obligations hereunder.

 

(b)
Company Representations, Warranties and Covenants. The Company hereby represents, warrants, agrees and covenants, as applicable,
to and with the Holder that:

 

(i)
Solvency. Neither the Company nor any of its subsidiaries has taken any steps to seek protection pursuant to any bankruptcy law
nor does the Company have knowledge that its creditors or its subsidiaries’ creditors intend to initiate involuntary bankruptcy
proceedings or knowledge of any fact which would reasonably lead a creditor to do so. The Company and its subsidiaries, individually
and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby will not
be, Insolvent. As used herein, “Insolvent” means, with respect to any Person, (i) the present fair saleable value
of such Person’s assets is less than the amount required to pay such Person’s total indebtedness, (ii) such Person is unable
to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii)
such Person intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or (iv)
such Person has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted
and is proposed to be conducted.

 

    	3

     

    

 

(ii)
Organization and Qualification. Each of the Company and each of its subsidiaries are entities duly organized and validly existing
and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authorization to own
their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of the Company
and each of its subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which
its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that
the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect. As used in
this Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets, liabilities,
operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries, individually
or taken as a whole, or on the transactions contemplated hereby or by the agreements and instruments to be entered into in connection
herewith, or on the authority or ability of the Company to perform any of its obligations hereunder.

 

(iii)
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its
obligations under this Agreement). The execution and delivery of this Agreement by the Company and the consummation by the Company of
the transactions contemplated thereby have been duly authorized by the Company’s Board of Directors and no further filing, consent
or authorization is required by the Company, its Board of Directors or its stockholders. This Agreement has been duly executed and delivered
by the Company, and constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance
with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’
rights and remedies.

 

(iv)
No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of
the transactions contemplated hereby (including, without limitation, the issuance of the Exercised Warrant Shares) will not (i) result
in a violation of the Company’s Certificate of Incorporation or Bylaws or other organizational documents of the Company or any
of its subsidiaries, any capital stock of the Company or any of its subsidiaries or the articles of association or bylaws of the Company
or any of its subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
agreement, indenture or instrument to which the Company or any of its subsidiaries is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and the rules
and regulations of Principal Market and including all applicable foreign, federal laws, rules and regulations) applicable to the Company
or any of its subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected.

 

    	4

     

    

 

(v)
Consents. The Company is not required to obtain any consent from, authorization or order of, or make any filing or registration
with any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations under or contemplated by this Agreement in accordance with the terms hereof. All consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the Closing Date, and the Company is unaware of any facts or circumstances which might prevent the Company from obtaining
or effecting any of the registration, application or filings contemplated by this Agreement. The Company is not in violation of the requirements
of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of
the Common Stock in the foreseeable future. The issuance by the Company of the Exercised Warrant Shares shall not have the effect of
delisting or suspending the Common Stock from the Principal Market.

 

(vi)
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by the Principal Market, any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against
or affecting the Company or any of its subsidiaries, the Common Stock or any of the Company’s subsidiaries or any of the Company’s
or its subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such.

 

(vii)
SEC Filings. As of their respective filing dates, the Company’s filings with the SEC under the 1934 Act during the two (2)
years prior to the date hereof (the “SEC Documents”), complied in all material respects with the requirements of the
1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents,
at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The Company represents that, as of the date hereof, no material event or circumstance has occurred which would be required
to be publicly disclosed or announced on a Current Report on Form 8-K, either as of the date hereof or solely with the passage of time
by the Company but which has not been so publicly announced or disclosed.

 

    	5

     

    

 

(viii) Disclosure
of Transactions and Other Material Information. The Company shall file a current report on Form 8-K (the “8-K
Filing”) on or before 8:30 a.m., New York City time, on May 13, 2022, in the form required by the 1934 Act, relating to
the transactions contemplated by this Agreement (including, without limitation, all schedules and exhibits to such agreement, if
any) as an exhibit to such filing. From and after the filing of the 8-K Filing with the SEC, the Holder shall not be in possession
of any material, nonpublic information received from the Company, any of its subsidiaries or any of their respective officers,
directors, Affiliates, employees or agents, that is not disclosed in the 8-K Filing. In addition, effective upon the filing of the
8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, Affiliates, employees
or agents, on the one hand, and the Holder or any of its Affiliates, on the other hand, shall terminate and be of no further force
or effect. The Company shall not, and shall cause each of its subsidiaries and its and each of their respective officers, directors,
Affiliates, employees and agents, not to, provide the Holder with any material, nonpublic information regarding the Company or any
of its subsidiaries from and after the date hereof without the express prior written consent of the Holder. To the extent that the
Company, any of its subsidiaries or any of their respective officers, directors, Affiliates employees or agents delivers any
material, non-public information to the Holder without the Holder’s express prior written consent, the Company hereby
covenants and agrees that the Holder’s shall not have any duty of confidentiality to the Company, any of its subsidiaries or
any of their respective officers, directors, Affiliates, employees or agents with respect to, or a duty to the Company, any of its
subsidiaries or any of their respective officers, directors, Affiliates, employees or agents not to trade on the basis of, such
material, non-public information. The Company understands and confirms that the Holder will rely on the foregoing representations in
effecting transactions in securities of the Company.

 

(ix)
No Integration Actions. None of the Company, any of its Affiliates or any Person acting on behalf of the Company or such Affiliate
will sell, offer for sale or solicit offers to buy in respect of any security (as defined in the 1933 Act) that would be integrated with
the issuance of the Exercised Warrant Shares in a manner that would require the registration under the 1933 Act of the issuance to the
Holder or require shareholder approval under the rules and regulations of the Principal Market, and the Company will take all action
that is appropriate or necessary to assure that its offerings of other securities will not be integrated for purposes of the 1933 Act
or the rules and regulations of the Principal Market.

 

(x)
Outstanding Shares. As of the date hereof, there are 188,052,593 shares of Common Stock issued and outstanding.

 

(xi)
Investment Company Status. The Company is not, and upon consummation of the transactions contemplated hereunder will not be, an
“investment company,” an affiliate of an “investment company, “ a company controlled by an “investment
company” or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment
company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

(xii)
Illegal or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the best of
the Company’s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents
or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with which the Company
or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution
or gift of money, property, or services, whether or not in contravention of applicable law, (i) as a kickback or bribe to any Person
or (ii) to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal
political contributions not involving the direct or indirect use of funds of the Company or any of its Subsidiaries.

 

    	6

     

    

 

(xiii)
Money Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act
of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation, the laws,
regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, but not
limited, to (x) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions With Persons
Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (y) any regulations contained in 31 CFR,
Subtitle B, Chapter V.

 

(xiv)
Acknowledgement Regarding Holder’s Trading Activity. It is understood and acknowledged by the Company that (i) following
the public disclosure of the transactions contemplated by this Agreement, in accordance with the terms thereof, the Holder has not been
asked by the Company or any of its Subsidiaries to agree, nor has the Holder agreed with the Company or any of its Subsidiaries, to desist
from effecting any transactions in or with respect to (including, without limitation, purchasing or selling, long and/or short) any securities
of the Company, or “derivative” securities based on securities issued by the Company or to hold any securities for any specified
term; (ii) the Holder, and counterparties in “derivative” transactions to which the Holder is a party, directly or indirectly,
presently may have a “short” position in the Common Stock which was established prior to such Holder’s knowledge of
the transactions contemplated by this Agreement; (iii) the Holder shall not be deemed to have any affiliation with or control over any
arm’s-length counterparty in any “derivative” transaction; and (iv) the Holder may rely on the Company’s obligation
to timely deliver shares of Common Stock upon conversion, exercise or exchange, as applicable, of the Exercised Warrants as and when
required pursuant to the terms thereof for purposes of effecting trading in the Common Stock of the Company. The Company further understands
and acknowledges that following the public disclosure of the transactions contemplated by this Agreement pursuant to the 8-K Filing the
Holder may engage in hedging and/or trading activities (including, without limitation, the location and/or reservation of borrowable
shares of Common Stock) at various times during the period that the Exercised Warrants or the shares of Common Stock issuable upon exercise
thereof are outstanding, including, without limitation, during the periods that the value and/or number of the such shares of Common
Stock deliverable thereunder are being determined and such hedging and/or trading activities (including, without limitation, the location
and/or reservation of borrowable shares of Common Stock), if any, can reduce the value of the existing stockholders’ equity interest
in the Company both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges that such
aforementioned hedging and/or trading activities do not constitute a breach of this Agreement or any of the documents executed in connection
herewith or therewith.

 

(xv)
Registration Statement. As of the Closing Date, the Company’s Registration Statement on Form S-1 (Registration No. 333-260080)
(x) shall be effective and available for use by the Holder for the sale of any shares issuable upon the exercise of any Exercised Series
A September 2021 Warrants, (y) will not contain, as of the Closing Date, any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading and (z) will comply in all material respects
with the 1933 Act and the applicable rules and regulations of the SEC thereunder.

 

	 	4.	CONDITIONS
    TO ComPANY’S OBLIGATIONs hereunder.

 

The
obligations of the Company to the Holder hereunder are subject to the satisfaction of each of the following conditions, provided that
these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing
the Holder with prior written notice thereof:

 

    	7

     

    

 

(a)
The Holder shall have duly executed this Agreement and delivered the same to the Company; and

 

(b)
The representations and warranties of the Holder shall be true and correct as of the date when made and as of the Closing Date as though
made at that time (except for representations and warranties that speak as of a specific date which shall be true and correct as of such
specified date), and the Holder shall have performed, satisfied and complied with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date.

 

	 	5.	CONDITIONS
    TO HOLDER’S OBLIGATIONs HEREUNDER.

 

The
obligations of the Holder hereunder are subject to the satisfaction of each of the following conditions, provided that these conditions
are for the Holder’s sole benefit and may be waived by the Holder in respect of itself at any time in its sole discretion by providing
the Company with prior written notice thereof:

 

(a)
The Company shall have duly executed this Agreement and delivered the same to the Holder;

 

(b)
The Company’s Registration Statement on Form S-1 (Registration No. 333-260080) shall be effective and available for use by the
Holder for the sale of any shares issuable upon the exercise of any Series A September 2021 Warrants;

 

(c)
The Company shall have obtained the listing of all of the Exercised Warrant Shares on each Eligible Market on which the Common Stock
is then listed for trading;

 

(d)
The representations and warranties of the Company under this Agreement shall be true and correct in all respects as of the date when
made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date
which shall be true and correct as of such specified date) and the Company shall have performed, satisfied and complied in all respects
with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at
or prior to the Closing Date;

 

(e)
The Common Stock (i) shall be designated for quotation or listed on the Principal Market and (ii) shall not have been suspended, as of
the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or the Principal
Market have been threatened, as of the Closing Date, either (A) in writing by the SEC or the Principal Market or (B) by falling below
the minimum listing maintenance requirements of the Principal Market;

 

(f)
Counsel for the Company shall have delivered a legal opinion to the Company’s transfer agent instructing the transfer agent to
deliver the Exercised Warrant Shares to the Holder’s balance account with The Depository Trust Company through its Deposit / Withdrawal
at Custodian system in accordance with the provisions of Section 2(a) hereof, and the Company’s transfer agent shall have delivered
the Exercised Warrant Shares to such balance account;

 

    	8

     

    

 

(g)
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the transactions
contemplated hereby; and

 

(h)
Since the date hereof, no event that could be reasonably expected to cause a Material Adverse Effect shall have occurred.

 

	 	6.	TERMINATION.

 

In
the event that the Closing shall not have occurred by on or before five (5) Business Days from the date hereof, other than due to the
Holder’s failure to satisfy the conditions set forth in Section 4 hereof, the Holder shall have the option to terminate this Agreement
at the close of business on such date without liability of any party to any other party. Upon such termination, the terms hereof shall
be null and void.

 

	 	7.	MISCELLANEOUS.

 

(a)
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of
this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of
any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action
or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing
a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.

 

(b)
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided
that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and
effect as if the signature were an original, not a facsimile signature.

 

    	9

     

    

 

(c)
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.

 

(d)
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by
a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended
to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall
not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express,
without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity
or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor
in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of
which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(e)
Entire Agreement; Amendments. This Agreement shall supersede all other prior oral or written agreements among the Holder, the
Company, their Affiliates and persons acting on their behalf with respect to the matters discussed herein and therein, and this Agreement,
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and
therein. The parties hereto agree that they will have deemed to have consented to any amendment, modification or waiver of this Agreement
if such amendment, modification or waiver was approved by an instrument in writing signed by the Company and Hudson Bay Master Fund Ltd.
unless such amendment, modification or waiver (x) disproportionately affects one or more holders of the Series A September 2021 Warrants
(it being understood that Hudson Bay Master Fund Ltd. holds other securities issued by the Company and may acquire other securities of
the Company in the future and Hudson Bay Master Fund Ltd. may receive consideration or benefits in its capacity as a holder of such other
securities without impacting such proportionality determination hereunder) or (y) imposes any financial obligation or liability on Hudson
Bay Master Fund Ltd. or the Holder without such party’s prior written consent (which may be granted or withheld in such party’s
sole discretion).

 

(f)
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement
must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party)
or electronic mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the
sending party does not receive an automatically generated message from the recipient’s email server that such e-mail could not
be delivered to such recipient); or (iii) three (3) Business Days after deposit with an overnight courier service with next day delivery
specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for
such communications shall be:

 

If
to the Company:

 

Vinco
Ventures, Inc.

6 North Main Street

Fairport, NY 14450

Telephone: (866) 900-0992

Facsimile: (908) 235-4373

Attention: Chief Executive Officer

E-Mail: Lking@Vincoventures.com

 

    	10

     

    

 

With
a copy (for informational purposes only) to:

 

Lucosky
Brookman LLP

101 Wood Avenue South, 5th Floor

Woodbridge, New Jersey 08830

Telephone: (732) 395-4400

Facsimile: (732) 395-4401

Attention: Joseph Lucosky, Esq.; Adele Hogan, Esq.

E-Mail: jlucosky@lucbro.com; ahogan@lucbro.com

 

If
to the Transfer Agent:

 

Nevada
Agency and Transfer Company

50 W. Liberty Street, Suite 880

Reno, Nevada 89501

Telephone: (775) 322-0626

Facsimile: (775) 322-5623

Attention: Tiffany Baxter

E-Mail: stocktransfer@natco.com

 

If
to a Holder, to its address, e-mail address and facsimile number set forth on the Schedule of Holders, with copies to such Holder’s
representatives as set forth on the Schedule of Holders,

 

with
a copy (for informational purposes only) to:

 

Schulte
Roth & Zabel LLP

919 Third Avenue

New York, New York 10022

Telephone: (212) 756-2000

Facsimile: (212) 593-5955

Attention: Eleazer N. Klein, Esq.

E-mail: eleazer.klein@srz.com

 

    	11

     

    

 

or
to such other address, e-mail address and/or facsimile number and/or to the attention of such other Person as the recipient party has
specified by written notice given to each other party five (5) days prior to the effectiveness of such change, provided that Schulte
Roth & Zabel LLP shall only be provided copies of notices sent to the lead Holder. Written confirmation of receipt (A) given by the
recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s
facsimile machine or e-mail containing the time, date, recipient facsimile number and, with respect to each facsimile transmission, an
image of the first page of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence of personal
service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(g)
Successors and Assigns. Notwithstanding anything to the contrary under the Series A September 2021 Warrants and the September
2021 WEA, this Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including
any purchasers of the Series A September 2021 Warrants or Exercised Warrant Shares, except to the extent any Exercised Warrant Shares
are sold in the open market; provided that no Exercised Warrant Shares may be sold in the open market before the Minimum Holding
Date.

 

(h)
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(i)
Survival. The representations, warranties and covenants of the Company and the Holder contained herein shall survive the Closing
and delivery of the Exercised Warrant Shares.

 

(j)
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

(k)
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

(l)
Fees and Expenses. The Company shall reimburse the Holder for its legal fees and expenses in connection with the preparation and
negotiation of this Agreement and transactions contemplated thereby, by paying any such amount to Schulte Roth & Zabel LLP (the “Holder
Counsel Expense”) by wire transfer of immediately available funds in accordance with the written instructions of Schulte Roth
& Zabel LLP delivered to the Company on or prior to the Closing. The Holder Counsel Expense shall be paid by the Company whether
or not the transactions contemplated by this Agreement are consummated. Except as otherwise set forth above, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all stamp and other taxes
and duties levied in connection with the transactions contemplated hereby, if any.

 

    	12

     

    

 

(m)
Minimum Holdings. The Holder hereby agrees to be the holder of a number of shares of Common Stock that is not less than the number
of Exercised Warrant Shares issued to the Holder pursuant to Section 1(a) until the earlier to occur of (i) June 17, 2022 and
(ii) the day after the record date with respect to the first annual or special meeting of the Company’s stockholders held after
the date hereof. For the avoidance of doubt, this Section 7(m) shall not restrict the Holder from selling, transferring or otherwise
disposing of any Exercised Warrant Shares issued to the Holder pursuant to Section 1(a) as long as the Holder continues to hold as of
the close of business on any Trading Day during the period specified in the immediately preceding sentence a number of shares of Common
Stock equal to the number of Exercised Warrant Shares issued to the Holder pursuant to Section 1(a).

 

(n) Amendment of September Warrants. The Company and the Holder hereby
agree, effective immediately prior to the exercise of the Exercised Warrants that Sections 2(b), 4(c), 19(c), 19(e), 19(h) and 19(o) of
the Series A September Warrant are each hereby and amended and restated, as follows: “Intentionally omitted”. This Section
7(n) shall supersede Section 7(o) of that certain Warrant Exercise Agreement dated as of December 20, 2021 by and between the Company
and the investor named therein.

 

(o)
Independent Nature of Buyers’ Obligations and Rights. The obligations of the Holder and each other holder of Series A
September 2021 Warrants are several and not joint with the obligations of the Holder, and the Holder shall not be responsible in any
way for the performance of the obligations of any other holder of Series A September 2021 Warrants under this Agreement or any agreement
contemplated hereby. Nothing contained herein or in any other agreement, and no action taken by the Holder pursuant hereto or thereto,
shall be deemed to constitute the Holder, the other holders of Series A September 2021 Warrants as, and the Company, and any subsidiary
thereof (as the case may be) acknowledges that the Holder and the other holders of Series A September 2021 Warrants do not so constitute,
a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that they are in any way
acting in concert or as a group or entity, and the Company and any subsidiary shall not assert any such claim with respect to such obligations
or the transactions contemplated by this Agreement or any other agreement contemplated hereby or any matters, and the Company and any
subsidiary thereof (as the case may be) acknowledges that the Holder and the other holders of Series A September 2021 Warrants are not
acting in concert or as a group, and the Company and any subsidiary thereof (as the case may be) shall not assert any such claim, with
respect to such obligations or the transactions contemplated by this Agreement or any other agreement contemplated hereby. The decision
of the Holder to enter into this Agreement has been made by the Holder independently of any other holder of Series A September 2021 Warrants.
The Holder acknowledges that no other holder of Series A September 2021 Warrants has acted as agent for the Holder in connection with
the Holder making its entering into this Agreement and that no other holder of Series A September 2021 Warrants will be acting as agent
of the Holder in connection with monitoring the Holder’s investment in the Exercised Warrants or Exercised Warrant Shares or enforcing
its rights under this Agreement or any other agreement contemplated hereby. The Company and the Holder confirms that the Holder has independently
participated with the Company and its subsidiaries in the negotiation of the transaction contemplated hereby with the advice of its own
counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement or out of any other agreement contemplated hereby, and it shall not be necessary for any other holder
of Series A September 2021 Warrants to be joined as an additional party in any proceeding for such purpose.

 

[Signature
Page Follows]

 

    	13

     

    

 

IN
WITNESS WHEREOF, the Holder and the Company have caused their respective signature pages to this Agreement to be duly executed as
of the date first written above.

 

	 	COMPANY:
	 	 
	 	VINCO
    VENTURES, INC.
	 	 	 
	 	By:	 
	 	Name:	Lisa
    King
	 	Title:
    	Chief
    Executive Officer

 

[Signature
Page to Warrant Exercise Agreement]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the Holder and the Company have caused their respective signature pages to this Agreement to be duly executed as
of the date first written above.

 

	 	HOLDER:
	 	 
	 	HUDSON
    BAY MASTER FUND LTD.
	 	 	 
	 	By:	            
	 	Name:	 
	 	Title:
    	 
	 	 	 
	 	Exercised Warrants:

	 	 

 

[Signature
Page to Warrant Exercise Agreement]

 

    	 

     

    

 

SCHEDULE
I

 

	(1)	 	(2)	 	(3)	 	(4)
	Holder
	 	Address
                                            and

                                            Facsimile Number
	 	DWAC
                                            Instructions
	 	Legal
                                            Representative’s Address and Facsimile Number

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]